Mohsen Tehrani
Overview
Explore the profile of Mohsen Tehrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dabiri M, Tehrani M, Rafiei A, Valadan R
Protein Expr Purif
. 2024 Dec;
228:106649.
PMID: 39722421
Background: Tumor cells exploit epidermal growth factor receptor (EGFR) family to develop resistance against therapeutic antibodies, such as Herceptin. Upon ligand binding, dimerization between EGFR and HER2 is one of...
2.
Keykhosravi M, Asgarian-Omran H, Valadan R, Tehrani M, Javadzadeh S, Taghiloo S, et al.
Asian Pac J Cancer Prev
. 2024 Aug;
25(8):2669-2677.
PMID: 39205564
Background: Previous studies have reported the role of the Herpes Virus Entry Mediator (HVEM) in various cancer including gastric cancer. However, the expression level and clinical significance of CD160 and...
3.
Rajabinejad M, Valadan R, Tehrani M, Najafi A, Negarandeh R, Saeedi M, et al.
Med Oncol
. 2024 May;
41(6):149.
PMID: 38739199
Because of the high biocompatibility, self-assembly capability, and CD71-mediated endocytosis, using human heavy chain ferritin (HFn) as a nanocarrier would greatly increase therapeutic effectiveness and reduce possible adverse events. Anti-PD-L1...
4.
Akbar A, Asgarian-Omran H, Valadan R, Dindarloo M, Najafi A, Kahrizi A, et al.
Iran J Basic Med Sci
. 2023 Nov;
26(12):1468-1474.
PMID: 37970435
Objectives: Exhausted CD8+ T-cells over-express immune checkpoint receptors (ICRs), which interact with their ligands on malignant cells. However, some ICRs have been reported to be expressed on both T-cells and...
5.
Mohammadi M, Asgarian-Omran H, Najafi B, Najafi A, Valadan R, Karami H, et al.
Iran J Immunol
. 2023 Nov;
20(4):438-445.
PMID: 37961948
Background: Thymocyte selection-associated high mobility group box protein (TOX) and members of the nuclear receptor 4A (NR4A) are known as transcription factors involved in T cell exhaustion. Objective: To evaluate...
6.
Najafi A, Valadan R, Asgarian-Omran H, Rafiei A, Tehrani M
Int Immunopharmacol
. 2023 Oct;
124(Pt B):110999.
PMID: 37804659
Dimer-dependent phosphorylation of HER2 receptor is a key event for the signal transduction of HER family of receptors which correlates with tumor invasion and metastasis. New generation of therapies based...
7.
Mohammadi M, Asgarian-Omran H, Najafi A, Valadan R, Karami H, Naderisoraki M, et al.
Iran Biomed J
. 2023 Aug;
27(4):214-8.
PMID: 37634081
Background: This study investigated the role of the immune-checkpoint receptor (ICR), CD244, and its adapter molecules, in CD8+ T cells in acute leukemia. Methods: Blood samples were obtained from 21...
8.
Najafi A, Sabaghi M, Asgarian-Omran H, Valadan R, Shekarriz R, Zaboli E, et al.
Asian Pac J Cancer Prev
. 2023 Jun;
24(6):2171-2176.
PMID: 37378949
Objective: BATF, as a transcription factor, and CD112, as a receptor for TIGIT, are involved in T-cell exhaustion. We investigated BATF and CD112 gene expression in the peripheral blood mononuclear...
9.
Valadan R, Dabiri M, Tehrani M, Tabar G, Rafiei A
J Immunol Methods
. 2023 Mar;
515:113456.
PMID: 36898519
Background And Objective: Overexpression of EGFR, a member of the ErbB receptor family, has been observed in several cancers and causes resistance to therapeutic antibodies, such as Herceptin. In this...
10.
Rahavi H, Alizadeh-Navaei R, Tehrani M
Immunotherapy
. 2023 Feb;
15(4):283-292.
PMID: 36789642
A comprehensive meta-analysis was conducted to explore the efficacy of TGF-β blockade therapies in solid tumors. Results of overall survival (OS), progression-free survival (PFS), time to progression (TTP) and overall...